Acceder

Publicaciones - INMUNOLOGÍA E INMUNOTOLERANCIA EN TRASPLANTES Y ENFERMEDADES DE BASE INMUNOLÓGICA

Cargando...
Garcia-Fernandez JJ, Sanchez-Nicolas JA, Galicia-Puyol S, Gil-Rosa I, Guerras-Conesa JJ, Bernal-Morell E, Cinesi-Gomez C. Failure of Non-Invasive Respiratory Support in Patients with SARS-CoV-2. J Clin Med. 2023 Oct 15;12(20):6537. doi: 10.3390/jcm12206537. PubMed PMID: 37892675; PubMed Central PMCID: PMC10607690.
AÑO: 2023
37892675
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Banaclocha HM, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia. Clin Transl Oncol. 2023 Jan 4. doi: 10.1007/s12094-022-03042-z. Online ahead of print. PubMed PMID: 36598635.
AÑO: 2023; IF: 3.4
36598635
Del Pozo-Valero M, Corton M, Lopez-Rodriguez R, Mahillo-Fernandez I, Ruiz-Hornillos J, Minguez P, Villaverde C, Perez-Tomas ME, Barreda-Sanchez M, Mancebo E; STOP_Coronavirus Study Group; Paz-Artal E, Guillen-Navarro E, Almoguera B, Ayuso C. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years. Geroscience. 2023 Feb;45(1):543-553. doi: 10.1007/s11357-022-00666-5. Epub 2022 Oct 3. PubMed PMID: 36184726; PubMed Central PMCID: PMC9527133.
AÑO: 2023; IF: 5.6
36184726
Suarez-Garcia I, Alejos B, Hernando V, Vinuela L, Vera Garcia M, Rial-Crestelo D, Perez Elias MJ, Albendin Iglesias H, Peraire J, Tiraboschi J, Diaz A, Moreno S, Jarrin I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice. J Antimicrob Chemother. 2023 Apr 26:dkad102. doi: 10.1093/jac/dkad102. Online ahead of print. PubMed PMID: 37099559.
AÑO: 2023; IF: 5.2
37099559
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, Bernal Morell E, Rentero Redondo L. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study. Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392-8. doi: 10.1016/j.gastrohep.2023.08.004. Online ahead of print. English, Spanish. PubMed PMID: 37597745.
AÑO: 2023; IF: 1.9
37597745
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

INMUNOLOGÍA E INMUNOTOLERANCIA EN TRASPLANTES Y ENFERMEDADES DE BASE INMUNOLÓGICA